This variant resides in the BARD1 RING finger domain (p.Cys74Phe), a critical functional domain required for BRCA1 heterodimerization and E3 ubiquitin ligase activity.¹ The variant is extremely rare in population databases: absent from gnomAD v2.1 and observed at 0.0092% (135/1,469,506 alleles, 0 homozygotes) in gnomAD v4.1, meeting PM2 threshold (<0.1%).² Multiple in silico predictors support a deleterious effect: REVEL score 0.932 (strongly damaging), BayesDel score 0.560 (moderately deleterious). No splicing impact is predicted (SpliceAI max delta 0.05).³ No functional studies have been reported for this variant. OncoKB reports unknown oncogenic effect. Six clinical laboratories in ClinVar classify this variant as Uncertain significance with 1-star review status.⁴ No de novo observations, segregation data, case-control enrichment, or same-residue pathogenic comparators were identified. No literature publication mentions this specific variant.⁵ Applying generic ACMG/AMP 2015 criteria: PM1 (RING domain) + PM2 (rare in population) + PP3 (in silico damaging) = 2 moderate + 1 supporting pathogenic criteria, with zero benign criteria met. This combination is insufficient for Likely Pathogenic classification and supports a classification of Uncertain significance.⁶